Free tool
FAERS Monitor: Zegfrovy
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219839 or its brand name (Zegfrovy, Sunvozertinib). Reports on generic versions are filed under their own applications.
Reports
41
Serious
41
100% of reports
Hospitalization
37
Death reported
3
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea6
- decreased appetite4
- mouth ulceration4
- platelet count decreased4
- pneumonia4
- pneumonitis4
- toxic epidermal necrolysis4
- chest discomfort3
- gastric perforation3
- oedema peripheral3
- rash3
- anaemia2
- asthenia2
- blood creatine phosphokinase increased2
- dermatitis exfoliative2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 1 |
| 2025 | 22 |
| 2026 | 18 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,118 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| gastric perforationSignal | 3 | 565.5 | 190.1 | 1,172 |
| dermatitis exfoliative | 2 | 205.1 | 53.1 | 228 |
| toxic epidermal necrolysisSignal | 4 | 135.2 | 53.3 | 407 |
| mouth ulcerationSignal | 4 | 97.4 | 38.4 | 292 |
| pneumonitisSignal | 4 | 75.4 | 29.7 | 224 |
| blood creatine phosphokinase increased | 2 | 35.6 | 9.2 | 37 |
| platelet count decreasedSignal | 4 | 19.3 | 7.6 | 52 |
| chest discomfortSignal | 3 | 15.0 | 5.1 | 27 |
| oedema peripheralSignal | 3 | 12.6 | 4.2 | 22 |
| decreased appetiteSignal | 4 | 8.8 | 3.5 | 21 |
| pneumoniaSignal | 4 | 6.3 | 2.5 | 13 |
| anaemia | 2 | 5.4 | 1.4 | 3 |
| diarrhoeaSignal | 6 | 4.8 | 2.3 | 15 |
| rash | 3 | 3.5 | 1.2 | 3 |
| asthenia | 2 | 2.7 | 0.7 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.